Calcium channels in neurological disease

Annals of Neurology

Volumn 42, Issue 3, 1997, Pages 275-282

  Greenberg, David A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION; RYANODINE RECEPTOR;

ATAXIA; CALCIUM MOBILIZATION; CEREBELLAR ATAXIA; CHANNEL GATING; EATON LAMBERT SYNDROME; GENE MUTATION; HEMIPLEGIA; HUMAN; HYPOKALEMIC PERIODIC PARALYSIS; MALIGNANT HYPERTHERMIA; MIGRAINE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CALCIUM CHANNELS; CALMODULIN-BINDING PROTEINS; GENE EXPRESSION; GENETIC DISEASES, INBORN; HUMANS; IMMUNE SYSTEM DISEASES; MUSCLE PROTEINS; NEUROMUSCULAR DISEASES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 0030799454     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420302     Document Type: Review

References (64)

1. Katz B. The release of neural transmitter substances. Liverpool: Liverpool University Press, 1969
2. Greenberg DA. Calcium channels and calcium channel antagonists. Ann Neurol 1987;21:317-330
3. 2+ channels in mammalian central neurons. Trends Neurosci 1995;18:89-98
4. Gurnett CA, Campbell KP. Transmembrane auxiliary subunits of voltage-dependent ion channels. J Biol Chem 1996;271:27975-27978
5. Olivera BM, Miljanich GP, Ramachandran J, Adams ME. Calcium channel diversity and neurotransmitter release: the ω-conotoxins and ω-agatoxins. Annu Rev Biochem 1994;63:823-867
6. Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 1995;35:707-734
7. 2+ channels. Trends Pharmacol Sci 1997;18:37-42
8. Olivera BM, Rivier J, Clark C, et al. Diversity of Conns neuropeptides. Science 1990;249:257-263
9. Mintz IM, Venema VJ, Swiderek KM, et al. P-type calcium channels blocked by the spider toxin ω-Aga-IVA. Nature 1992;355:827-829
10. Turner TJ, Adams ME, Dunlap K. Calcium channels coupled to glutamate release identified by ω-Aga-IVA. Science 1992;258:310-313
11. 2+ channels in supporting hippocampal synaptic transmission. Science 1994;264:107-111
12. 2+ release channel. J Biol Chem 1993;268:13765-13768
13. Chavis P, Fagni L, Lansman JB, Bockaert J. Functional coupling between ryanodine teceptors and L-type calcium channels in neurons. Nature 1996;382:719-722
14. 2+-release channels. Trends Pharmacol Sci 1994;15:145-149
15. 2+ release. Trends Pharmacol Sci 1995;16:386-391
16. Online Mendelian Inheritance in Man, OMIM (TM). Center for Medical Genetics, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 1997. World Wide Web URL: http://www.ncbi.nlm.nih.gov/Omimt
17. Hess EJ. Migraines in mice? Cell 1996;87:1149-1151
18. Ptacek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994;77:863-868
19. Jurkat-Rott K, Lehmann-Horn F, Elbaz A, et al. A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet 1994;3:1415-1419
20. Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNLIA3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 Caucasian families. Am J Hum Genet 1995;56:374-380
21. Boerman RH, Ophoff RA, Links TP, et al. Mutation in DHP receptor alpha-1 subunit (CACLNIA3) gene in a Dutch family with hypokalaemic periodic paralysis. J Med Genet 1995;32:44-47
22. Plassart E, Elbaz A, Santos JV, et al. Genetic heterogeneity in hypokalemic periodic paralysis (hypoPP). Hum Genet 1994;94:551-556
23. Elliott MA, Peroutka SJ, Welch S, May EF. Familial hemiplegic migraine, nystagmus, and cerebellar atrophy. Ann Neurol 1996;39:100-106
24. Joutel A, Bousser M-G, Biousse V, et al. A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 1993;5:40-45
25. Ophoff RA, van Eijk R, SandkuijI LA, et al. Genetic heterogeneity of familial hemiplegic migraine. Genomics 1994;22:21-26
26. Hovatta I, Kallela M, Färkkilä M, Peltonen L. Familial migraine: exclusion of the susceptibility gene from the reported locus of familial hemiplegic migraine on 19p. Genomics 1994;23:707-709
27. Joutel A, Ducros A, Vahedi K, et al. Genetic heterogeneity of familial hemiplegic migraine. Am J Hum Genet 1994;55:1166-1172
28. May A, Ophoff RA, Terwindt GM, et al. Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine with and without aura. Hum Genet 1995;96:604-608
29. 2+ channel gene CACNL1A4. Cell 1996;87:543-552
30. Fletcher CF, Lutz CM, O'Sullivan CM, et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996;87:607-617
31. Griggs RC, Nutt JG. Episodic ataxias as channelopathies. Ann Neurol 1995;37:285-287
32. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995;378:403-406
33. Timchenko LT, Caskey CT. Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues. FASEB J 1996;10:1589-1597
34. 1A-voltage-dependent calcium channel. Nat Genet 1997;15:62-69
35. MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992;256:789-794
36. Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991;253:448-451
37. 2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J Biol Chem 1994;269:9413-9415
38. MacLennan DH. Discordance between phenotype and genotype in malignant hyperthermia. Curr Opin Neurol 1995;8:397-401
39. 2/δ-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 1994;3:969-975
40. Shuaib A, Paasuke RT, Brownell AKW. Central core disease: clinical features in 13 patients. Medicine 1987;66:389-396
41. Zhang Y, Chen HS, Khanna VK, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993;5:46-50
42. Quane KA, Healy JMS, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993;5:51-55
43. Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci 1989;12:496-502
44. Lang B, Newsom-Davis J, Wray D, Vincent A. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981;2:224-226
45. Fukunaga H, Engel AG, Lang B, et al. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983;80:7636-7640
46. Kirn YI, Neher E. IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science 1988;239:405-408
47. Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739-749
48. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474
49. Mygland A, Tysnes OB, Matre R, et al. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neural 1992;32:589-591
50. Mygland A, Kuwajima G, Mikoshiba K, et al. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995;62:79-83
51. Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:843-846
52. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62
53. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
54. Smith RG, Hamilton S, Hofmann F, et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engt J Med 1992;327:1721-1728
55. Llinás R, Sugimori M, Cherksey BD, et al. IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer. Proc Natl Acad Sci USA 1993;90:11743-11747
56. Vincent A, Drachman DB. Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels-new doubts. Ann Neurol 1996;40:691-693
57. Arsac C, Raymond C, Martin-Moutot N, et al. Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum. Ann Neurol 1996;40:695-700
58. Nyormoi O. Proteolytic activity in amyotrophic lateral sclerosis IgG preparations. Ann Neurol 1996;40:701-706
59. Greenberg DA. Calcium channel antagonists and the treatment of migraine. Clin Neuropharmacol 1986;9:311-328
60. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Br Med J 1989;298:636-642
61. Kaste M, Fogelholme R, Erilä T, et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994;25:1348-1353
62. Bebin M, Bleck T. New anticonvulsant drugs: focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs 1994;48:153-171
63. 2+ channel β subunit gene Cehb4 is associated with ataxia and seizures in lethargic (lb) mouse. Cell 1997:88:385-392
64. Gardner K, Ptacek LJ, Hoffman EP. A new locus for hemiplegic migraine is a chromosome 1q31. Paper presented at 8th Congress of the International Headache Society, Amsterdam, June 10-14, 1997